Natco Pharma’s latest announcement isn’t just about slashing drug prices—it could redefine how investors value the stock.The Hyderabad-based generics company said it plans to launch Risdiplam, a generic of Roche’s Evrysdi, for ₹15,900 in India. That’s not a typo: it undercuts the ₹18 million annual cost of the branded version by more than 99.9%. While the drug hasn’t yet hit the market, the Delhi High Court has ordered a status quo pending patent litigation, and Natco has already signalled a strategic pivot.
.png)
